Fagron Compounding Services dba Fagron Sterile Services, Wichita, KS

Is Fagron Compounding Services dba Fagron Sterile Services an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Fagron Compounding Services dba Fagron Sterile Services in Wichita, KS, first registered Oct 2, 2015 and most recently registered Nov 21, 2025. FDA lists its last inspection as Aug 8, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Regulatory Meeting Held 2/27/2026”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Wichita, KS
Initial registration
Oct 2, 2015
Most recent registration
Nov 21, 2025
Last inspection
Aug 8, 2025
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Regulatory Meeting Held 2/27/2026
Intends to compound sterile drugs from bulk substances
Yes

FDA inspections and actions on record

No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Fagron Compounding Services, Wichita, KS (FEI number 3012104093), matched to this page by exact name, city and state. It lists 5 inspections: 4 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 8, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30121040931273014
Jun 28, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30121040931244425
Mar 24, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30121040931167657
Jun 21, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30121040931093689
Sep 21, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3012104093987526

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 34 numbered observations in all, across 5 inspections ending Sep 21, 2016 to Aug 8, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 29, 2025 to Aug 8, 2025: 6 observations

Firm on the cover
Fagron Compounding Services, 8710 E 34th St N, Wichita, KS 67226-2636
FEI number
3012104093
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
8050 Marshall Drive, Suite 205 Lenexa, KS 66214
Matched to this page by
FEI number on the cover; linked from 503B list, Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of diug products pmpo1ting to be sterile are not established, written and followed.

Specifically,

A. Your firm produces and releases drugs made after failed media fills and before successful revalidation of the aseptic processes. For example, on 3/7/2025, your firm documented suspected growth in <Redacted B4> media fill vials for study <Redacted B4> which was to validate the aseptic production process for Methylprednisolone Acetate 80mg/mL Injection suspension preservative free lmL (single dose vials). Your firm was unable to subculture the material in the vials when attempted and the observed particulate could not be identified as the samples were inadvertently discarded. No root cause could be determined. Your firm manufactured <Redacted B4> batches of the Methylprednisolone Acetate drug product after the failing media fill results were obtained. Three of thet <Redacted B4> lots were released for customer distribution (lot <Redacted B4> (BUD: 7/9/2025), lot <Redacted B4> (BUD:7/9/2025), and lot <Redacted B4> (BUD:8/6/2025)). Media fill deficiencies were noted during the 2024 FDA inspection.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Inadequate investigations were noted during the 2024 FDA inspection.

A. Since September 2024, your firm has documented 14 sterility positive investigations for products tested in your microbiology laboratory. Four sterility positive investigations were for product made at your Canton, MA, facility, while 10 investigations were for product made at the Wichita, KS, facility. Your firm has opened multiple action items and corrective and preventative actions to address the sterility positive events and identified multiple potential root causes to include deficiencies with the sterility testing <Redacted B4> systems and inadequate material disinfection during production activities as documented in action items AI-2025-0268, AI-2025-0270, and CAPA-2024-0181. Your opened CAPA-2025-0139 in July 2025 due to the ongoing sterility failures and your firm continues to sterility test drugs intended to be sterile. No definitive root cause(s) have been identified. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Buildings used in the manufacturing, processing, packing and holding of a drug product are not maintained in a good state of repair.

Specifically,

Your firm does not maintain production areas and associated equipment adequately. The following were noted during the inspection on 7/29/2025 and 7/30/2025:

• Unknown black discoloration within the ISO-5 area of the fill hood for Fill Line <Redacted B4> • What appeared to be rust on a cart holding scale calibration weights used for compounding (ISO-8).

• What appeared to be rust on fasteners/bolts within ISO-7 material passthroughs in rooms 323 and 340.

• Dark preenish fuzzy spots were observed on the light fixtures and status tag of cold room <Redacted B4>, which is utilized to store retain samples and finished product before distribution. Units from Vancomycin HCl in sodium chloride injection IV bags from lot <Redacted B4> (Expiry 1/17/2025) were observed in the room.

Observation 4

The number of qualified personnel is inadequate to perform the manufacture of each drug product.

Specifically,

Your firm does not have adequate resources to conduct environmental monitoring (EM) excursion investigations in a timely manner. As of 7/29/2025, your firm has over 64 open EM excursions investigations. Your firm has documented in associated deviation investigation extension requests the inability to complete the investigations due to inadequate time and prioritizing investigations for priority batches. Open EM investigations include excursions in critical ISO-5 filling areas such as deviation DEV-2025-1523, which was opened on 6/18/2025 for recovery of filamentous fungi (Penicillium citrinum, 1 CFU) from a passive viable air sample in the ISO-5 hood during production of Vancomycin IV bag lot <Redacted B4> (BUD: 12/7/2025).

Observation 5

Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable size to facilitate cleaning, maintenance, and proper operations.

Specifically,

Your firm lacks adequate ISO-7 storage space for staged production materials. You utilize aseptic fill room <Redacted B4> for storage and staging of production material (IV bags, syringes, <Redacted B4> water bags) when the room is not being utilized for Avastin Injection (1 .25 mg/0.05 mL). On 7 1572025, your firm stored <Redacted B4> carts of various production items in fill roonm <Redacted B4> as shown on video. Ten of the <Redacted B4> carts were pushed within the ISO-5 boundary of the fill room. Your operator cleaned the floor and walked and rolled the carts over the floor while the floor was still visibly wet, which is prohibited per procedure FSS-SOP-0227 "Site Cleaning, Sanitization and Disinfection Policy". Your firm subsequently utilized the fill room to produce Avastin Injection lot <Redacted B4> (BUD: 12/12/2025).

Observation 6

Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a diug product.

Specifically,

Procedure FSS-SOP-0369 "Use, Operation, and Cleaning of the <Redacted B4> Syringe Filling Machine" is inadequate as it lacks detailed cleaning instructions prior to equipment use to include instructions on cleaning the critical ISO-5 areas first, followed by the remainder of the equipment. The cleaning of the <Redacted B4> equipment observed on video for 7/15/2025, showed operators place multiple <Redacted B4> wipes on the base/deck of the equipment. The operators subsequently utilized the wipes to clean various areas within the ISO-5 to include the critical fill area. The equipment was then utilized to fill Avastin Injection lot <Redacted B4> (BUD: 12/12/2025).

Inspection Jun 18, 2024 to Jun 28, 2024: 7 observations

Firm on the cover
Fagron Compounding Services, LLC dba Fagron Sterile Services, 8710 E 34th St N, Wichita, KS 67226 -2636
FEI number
3012104093
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
8050 Marshall Drive, Suite 205 Lenexa, KS 66214
Matched to this page by
FEI number on the cover; linked from Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purportiing to be sterile are not established, written and followed.

Specifically,

A. Your firm released batches of sterile drug products even though positive microbial growth was detected during environmental monitoring (EM) and personnel monitoring (PM) in the ISO 5 aseptic area during batch processing. For example, since 2023, your firm has released a total of 9 batches with positive growth identified on operators' gloved hands, settle plates, or active air samples in the IS O 5 areas for the following products: Your investigation indicated that syringes and IV bags were filled in a minimally exposed environment for these batches, unlike vials and eye droppers; however, there is no assurance that product sterility was maintained throughout batch processing.

• Ketamin 10 mg/ml (API) 5 ml Fill in 5 rnL Syringe, Lot# <Redacted B4>, 1 CFU of Staphylococcus capitis identified on the right surface sample

• PHENYLeplnine 0. l mg/rnL PF Inj Soln I0rnL Syringe API, Lot# <Redacted B5>, 1 CFU of Staphylococcus epidermitis identified on the left hand ...

Read the full 483 (PDF on fda.gov)

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure ofa batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Your investigations ofout-of-specification (OOS) results in environmental monitoring (EM), visual inspection failures, and consumer complaints were inadequate for the following:

• Since 2023, your firm has reported 22 deviations due to OOS results of gloved hands, settle plates, or active air monitoring in the ISO 5 areas during aseptic batch processing. No definite root causes were identified and therefore no CAPAs were initiated for any of these EM OOS results. For example, your firm reported 1 CFU of Chaetomimn globosum on the right glove of an aseptic technician during the production of orepinephrine Bitartrnte 8mg added to 250mL0.9% NaCl Bag, Lot# <Redacted B4> dated February 1, 2024 (DEV-2024-0174). Since no definite root causes have been identified for the OOS result, the batch was rejected, and no CAPA was initiated.

plates, or active air monitoring in the ISO 5 areas during aseptic batch processing. ...

Read the full 483 (PDF on fda.gov)

Observation 3

The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically,

A. Your <Redacted B4> certifications of HEPA filters conducted in January 2024 and January 2023 identified HEPA filter leaks and/or discoloration in the ISO 5 aseptic processing areas; however, no CAPA has been initiated to prevent similar situations from reoccurrence.

B. No risk assessment or change control has been initiated for the impact of ongoing adjacent construction on sterile manufacturing. Your firm plans to construct an adjacent <Redacted B4> expansion to the east of the FSSE facility at 8720 East 34th St. Nmth, !05 <Redacted B4> facility upon completion. The construction has stained in the second quarter of 2024, with a target completion date of <Redacted B4>. However, yom firm has not initiated a change control for this project, stating that a change control will be initiated once the new const:Iuction <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Complaint records are deficient in that they do not include the findings of the investigation and follow-up.

Specifically

Customer complaint investigations are inadequate because your firm did not thoroughly investigate batches and provide supporting data to determine if a complaint is related to a quality issue. Since 2022, yom firm has received complaints about potential infections after using sterile drug products produced at yom facility, as follows:

• COMP-2022-0423: endophthalmitis following the administration of Avastin Solution forInjection, 2.5 mg/0.1 mL. 0.12mL Fill, Lot# <Redacted B4> dated June 22, 2022

• COMP-2023-0671: infection flowing the administration of Moxifloxacin HCl(Avelox) l .6mg/mL lmL fill in 3mL Syringe, Lot# <Redacted B4> dated September 14 2023

• COMP-2023-0680: spinal meningitis following the administration of TRIAMcinolone acetonide 40 mg/mL Inj Susp PF lmL SDV, Lot# <Redacted B4> dated September 18, 2023

• COMP-2024-0250: diffuse corneal swelling following the administration of Lidocaine 1 %/Phenylephrine 1.5% BSS PF/SF Inj Soln lmL SYR Lot# <Redacted B4> dated May 17, 2024 ...

Read the full 483 (PDF on fda.gov)

Observation 5

Laboratory controls do not include the establishment of scientifically sound and appropriate designed to assure that conform to appropriate standards of identity, strength, quality and purity.

Specifically,

During the walkthrough of the warehouse where <Redacted B4> incubators were located, I observed that all enviromnental monitoring <Redacted B4> plates were placed in a <Redacted B4> for incubation without any visible gaps. For example, I observed EM plates for Moxifloxacin HCl (Avelox) l.6mg/mL lmL fill in 3mL Syringe, Lot# <Redacted B4> were placed in a <Redacted B4> for incubation. Currently, all environmental monitoring samples collected during production of sterile drng products were placed in <Redacted B4> for microbial growth testing in these <Redacted B4> incubators. However, your firm has not validated this method using known bacterial strains under the same conditions. Your growth promotion testing was conducted in the microbiology laboratory in a different location using real plates that were unsealed. There is no documented evidence or study demonstrating the impact of this practice on bacterial and fungal growth. ...

Read the full 483 (PDF on fda.gov)

Observation 6

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(IO)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Specifically

The dosage firm is not included on some of your drug product labels.

For example, labels for the following drug product do not contain this information:

• Tropicamide 1 %/Cyclopentolate 1 %/Phenylephrine 2.5%/Ketorolac 0.5%, 5 mL in Multi-Dose Dropper Bottle (NDC# 71266-8240-05)

• Fentanyl Citrate 2 mcg/mL (100 mcg/50 mL)/Ropivacaine HCl 0.15% (1.5 mg/mL) (75 mg/50 mL), PF, for epidural use only (NDC# 71266-9235-01)

Observation 7

The container of your outsourcing facility's drug products does not include information required by section 503B(a)(IO)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Specifically,

Your containers do not include the following information:

A. Directions for use, including, as appropriate, dosage and administration. Specifically, the route of administration is not included on your containers. Examples of your container labels that do not contain this information include:

• Lidocaine 1 % (10 mg/mL)/Phenylephrine 1.5% (15 mg/mL) in BSS, PF/SF Injection, 1 mL in 3 mL Single-Use Syringe (NDC# 71266-6360-01)

• Epinephrine (1 mg/mL), Sterile Solution for Injection, PF/SF, 1 mL in Single-Use Syringe (NDC #7 1266-8120-01)

• Phenol Injection 6% (60 mg/mL), In Sterile Water for Injection, 10 mL in Multi-Dose Vial (NDC# 71266-6519-01 )

• Iohexol (Omnipaque) 300 mgI/mL, Sterile Aqueous Injection, PF, Repackaged, 3 mL in Single­Use Vial (NDC# 71266-6488-03)

• Iohexol (Omnipaque) 240 mgI/mL, Sterile Aqueous Injection PF, Repackaged, 5 mL in Single­Use Vial (NDC# 71266-6487-05)

• Sodium Citrate Injection 4% (40 mg/mL) 30 mL in Multi-Dose Vial (NDC# 71266-6641-01) ...

Read the full 483 (PDF on fda.gov)

Inspection Mar 1, 2022 to Mar 24, 2022: 6 observations

Firm on the cover
Fagron Compounding Services, 8710 E 34th St N, Wichita, KS 67226-2636
FEI number
3012104093
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
250 Marquette Ave, Ste. 600 Minneapolis, MN 55401
Matched to this page by
FEI number on the cover; linked from Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

a.

On 3/7/22 we observed a re-production cleaning video from 3/1/22 of the ISO 5 Horizontal laminar flow hood in fil <Redacted B4> room <Redacted B4> where the inside back of the hood was not cleaned prior to producing Moxifloxica.n Lot # <Redacted B4>.

b.

On 3/7/2022 we visually observed the cleaning of the ISO 5 Horizontal laminar flow hood in fill room <Redacted B4> where the inside back of the hood was not cleaned prior to producing Norepinephrine Bitartrate 32 mcg/mL (8mg/250mL) 250mL Bag Lot # <Redacted B4>.

c.

On 3/4/22 we observed the <Redacted B4> cleaning video from 1/20/22 and the <Redacted B4> cleaning video from 3/1/22 of Fill room <Redacted B4> an ISO 7 Cleanroom where the side of a wall protrusion, the wall above, behind and below the ISO 5 hood a stainless-steel protruding box on the wall, and the floor area under the pump cart was not cleaned.

d. ...

Read the full 483 (PDF on fda.gov)

Observation 2

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

Specifically,

No equipment qualification was performed at your facility upon relocation of equipment. The <Redacted B4> used for <Redacted B4> was decommissioned at the <Redacted B4> transferred to <Redacted B4> on or around January of 2020. The <Redacted B4> from this <Redacted B4> is used in the production of Sodium Thiosulfate 25% at your facility.

The Master batch record for Sodium Thiosulfate 25% solution states <Redacted B4> temperature should be above <Redacted B4> once it <Redacted B4> bag however the asset number <Redacted B4> for the <Redacted B4> used to <Redacted B4> is not recorded in the batch record as shown in Batch Lot # <Redacted B4> produced <Redacted B4>. Furthermore, your procedure FSS-SOP-0335, Use, Cleaning and Operation of the <Redacted B4>, mentions a program for the <Redacted B4> that <Redacted B4> to <Redacted B4> but does not mention a program for <Redacted B4> to <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Written procedures are not established that describe the in-process controls and examinations to be conducted on appropriate samples of in-process materials of each batch.

Specifically,

A. On 03/04/2022 we observed two technicians dump vials that were used for a personnel media fill operator qualification into a bin prior to performing final inspection of the vial. This process causes agitation of the vials prior to the inspection and could distmb microbial growth in the vial and inhibit detection of organisms. Procedure FSS-SOP-0341 , Training Course Plan-Media Fill Inspection, does not mention how technicians should perform inspections on vials, only that the technician "inspects all Acceptable and Integral rejects to verifies [sic] any <Redacted B4> and <Redacted B4>. This procedure is used for identifying positive growth units from Operator Qualifications and Process Simulation Media Fills.

B. On 03/04/2022 we observed technicians check for <Redacted B4> on vials that were used for a media fill operator qualification by holding them up towards the lighting positioned near the ceiling of a <Redacted B4> warehouse. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically,

There is no testing of the preservative content in the multiple dose injectable drug products at time of release. The following injectable solutions contain preservatives:

Sodium Citrate 4% lnj Soln 30ml Multiple-Dose Vial Injection contains <Redacted B4> as a preservative

Sodium citrate 4% Gentamicin 320mcg/ ml lnj Soln 30ml MDV contains <Redacted B4> as a preservative

Phenolin <Redacted B4> lnj Soln, 6%, 10-mL Multiple-Dose Vial contains <Redacted B4> as a preservative

Observation 5

The establishment of laboratory control mechanisms including any changes thereto are not reviewed and approved by the quality control unit.

Specifically,

On 03/02/2022 it was observed that lab notebooks used to record temperature and incubation times of Environmental Monitoring samples and media fills are not routinely reviewed the quality unit. The lab notebooks for incubator <Redacted B4> and <Redacted B4> have not been reviewed by QA prior to Janmuy of 2021. Furthermore, documentation fields in the lab books were blank and marked for correction; fields left blank and marked for conection included date reviewed by, temperature of incubator, date which media was incubated or removed from incubator, activity performed, and write overs that were not corrected.

reviewed by QA prior to Janmuy of 2021. Fmihennore, documentation fields in the lab books were blank and marked for correction; fields left blank and marked for conection included date reviewed by, temperature of incubator, date which media was incubated or removed from incubator, activity peif01med, and write overs that were not corrected.

Observation 6

Your outsourcing facility compounds drug products using bulk drug substances that cannot be used in compounding under section 503B because they (a) are not used to compound drug products that appear on the drug shortage list in effect under section 506E of the Act and (b) do not appear on a list developed by FDA of bulk drug substances for which there is a clinical need.

Specifically,

You produced the following products:

1. Glycopyrrolate 0.2 mg/ml (API) 1 mg per 5 ml in a 5 ml syringe (produced <Redacted B4>)

2. Glycopyrrolate 0.2 mg/ml (API) 0.6 mg per 3 ml in a 5 ml syringe (produced <Redacte d B4>)

Inspection Jun 10, 2019 to Jun 21, 2019: 11 observations

Firm on the cover
Fagron Compounding Services LLC dba Fagron Sterile Services, 8710 E 34th St N, Wichita, KS 67226-2636
FEI number
3012104093
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
8050 Marshall Drive, Suit e 205 Lenexa, KS 6621 4
Matched to this page by
FEI number on the cover; linked from Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent that would alter the safety, identity, strength, quality or purity of the drng product.

Specifically,

A) On 6/12/19 during a walkthrough of your firm's aseptic processing areas, I observed in <Redacted B4> laminar flow hood (Equiement ID#FSS-1050) cleanroom suite <Redacted B4> a brown/black residue on the inside of the LFH bottom left <Redacted B4> panel between the panel and the metal bench table lip edge. (Photograph taken) Aseptic processing of Glycopynolate 0.2mg/ml injection 5 ml syringes, batch <Redacted B4> was being aseptically filled at this time.

B) On 6/12/19 during a walkthrough of your firm's aseptic processing areas, I observed in <Redacted B4> laminar flow hood (Equipment ID# FSS-1053) cleanroom suite <Redacted B4> lcracked <Redacted B4> side panels from the overtightening of two connecting screws. In the cracking area around the screws a brown residue was observed. (Photograph taken) Aseptic processing of Succinylcholine chloride injection 20mg/ml batch# <Redacted B4> was being aseptically filled at the time.

Observation 2

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically,

There is no testing of the preservative content in the injectable drug products at time of release or during beyond use dating studies. The following injectable solutions contain preservatives:

Neostigmine Methylsulfate lmg/ml injection contains phenol as a preservative

Glycopynolate 0.2 mg/ml injection contains benzyl alcohol as a preservative

Sodium citrate 4% solution contains <Redacted B4> as a preservative

I Sodium citrate 4%/Gentamicin 320 mcg/ml contains <Redacted B4> as a preservative

Ketamine 50 mg/ml contains benzethonium chloride as a preservative

Observation 3

Protective apparel is not worn as necessary to protect drug products from contamination.

Specifically,

On 6/12/19 and again on 6/13/19, I observed aseptic operators in the clean room suites <Redacted B4> and~ respectively; wearing a goggle type in the ISO 5 <Redacted B4> laminar flow hood which contained numerous holes (approximately 50) for direct venting. Aseptic operators were at the time performing aseptic filling for sodium thiosulfate in 50 ml vials (Suite <Redacted B4> and a development batch for morphine 3ml synnges.

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

The monitoring for non-viable particulates is not located in close proximity to the aseptic operator located on the <Redacted B4> side of the laminar flow hood performing aseptic manipulations. The particle counter is located on the <Redacted B4> of the <Redacted B4> laminar flow hood. Two operators work simultaneously on the right and left side of the bench. The non-viable particle counter position is not in close proximity of the aseptic manipulations for the aseptic technician on the <Redacted B4> side of the laminar flow hood.

Observation 5

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically,

Media Fill study FSS 2018-030 (11/2018) for the 10 ml syringe, 5 ml fill does not contain information results of the incubated <Redacted B4> Y units and the conclusionaiy results of the media fill. There is no final report describing study results, if positive units were found and if the media fill met the protocol acceptance ciiteria.

Observation 6

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Investigations are not complete and do not always include a full investigation. Out of specification investigations do not include a review of the manufacturing process as required by your SOP 1.040.FSS, revision 2.0.

For example, the following OOS investigations were incomplete:

a) Neostigmine methylsulfate lot# C74-00010275 compounded on 4/30/19, Beyond Use Date 9/27/2019 received an OOS for assay with a result of 115.6% (limits <Redacted B4> %). No assignable root cause in the initial lab investigation. The original sample vial was <Redactted B4> and a revial of the original sample prep were performed, results were 115.2% and 115.5%, respectively. This confirms the original OOS. A triplicate retest was performed along w!th a 4th confirmatory test. All within specifications <Redacted B4> %. A <Redacted B4> test was applied and considered the original result an outlier. The original result was invalidated. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Packaged and labeled products are not examined during finishing operations to provide assurance that containers and packages in the lot have the corrected label.

Specifically,

Your fnm does not collect a representative number of finished drug products for an evaluation and documentation of correct labeling.

Observation 8

Adverse drug event information has not been reported to FDA.

Specifically , Your firm has received 16 complaints of serious unexpected events concerning lack of pharmacological effect which has not been reported to the FDA.

Year 2019:

Complaint#

Description

Product name

Lot

0319 -023,0319-032

Lack of effect

Rocuronium bromide injection lOmg/ml

C274 -000008848, C274-000008698

Lack of effect

Rocuronium bromide injection lOmg/ml

C274 -000009444

Lack of effect

Rocuronium bromide injection lOmg/ml

C274 -000008690

Lack of effect

Rocuronium bromide injection lOmg/ml

C274 -000008796

Lack of effect

Succinylcholine Chloride 20mg/ml

C274 -000009398

Lack of effect

Rocuronium bromide injection lOmg/ml

C274

Lack of effect

Rocuronium bromide injection lOmg/ml

C274 -000009597

Lack of effect

Rocuronium bromide injection lOmg/ml

C274

Lack of effect

Rocuronium bromide injection 10mg/ml

C274-000009325

injection 10mg/ml 000009325 0619-002

Lack of effect

Phenylephrine HCL 100mcg/ml C274-000009992

C274 -000009992

Year 2018:

Complaint#

Description

Product name

Lot

Lack of effect

Succinylcholine Chloride 20mg/ml

C274 -000006623

Lack of effect

Phenylephrine HCL l00mcg/ml

C274 -000006801

Lack of effect ...

Read the full 483 (PDF on fda.gov)

Observation 9

Your firm compounded drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2). Specifically, you compound chug products that are identical or nearly identical to an approved drug that is not on the drug shortage list in effect under section 506E at the time of compounding, distribution, and dispensing;

Examples of compounded drug products that are essentially a copy of one or more approved drugs include:

Drug name Package description

I Dosage f01m

Route of Administration

I

description f01m Administration Glycopynolate 0.2 mg/ml

5ml in syringe

Injection

Intravenous

Phenylephrine HCL 10mg/ml

10ml in syringe Injection

Intravenous

Neostigmine Methylsulfate lmg/ml

5ml in s yringe

Injection

Intravenous

Succinylcholine Chloride 20mg/ml

10ml in syringe

Injection

Intravenos

Observation 10

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l 0)(A). Specifically, your product labels do not include a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. If there is no space on the product label, such information should be included on the container per section 503B(a)(10)(B)(i).

Examples of your drug product labels that do not contain this information:

Sodium thiosulfate 25% injection

Lidocaine hychochloride 2% injection

Lidocaine hydrochloride 1 % injection

Ketamine hydrochloride 50 mg/mL injection

Succinylcholine chloride 20 mg/mL injection

Neostigmine methylsulfate 1 mg/mL injection

Glycopyrrolate 0.2 mg/mL injection

Rocuronium bromide 10 mg/mL injection

The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(l 0)(B). Specifically, your containers do not include the route of administration.

Examples of your container labels that do not contain this information.

Sodium thiosulfate 25% injection

Sodium citrate 4% injection containing gentamicin 320 mcg/mL

Sodium citrate 4% injection

Observation 11

Bulk drug substances used by your outsourcing facility to compound drug products are not each manufactured by an establishment that lS registered under section 510 as required by section 503B(a)(2)(C).

Specifically, the Trisodium citrate dihydrate API used in the manufacture of Sodium citrate 4% solution injection and Sodium citrate 4%/Gentamicin 320 mcg/ml solution injection is not manufactured in a FDA registered facility.

Inspection Aug 29, 2016 to Sep 21, 2016: 4 observations

Firm on the cover
Fagron Compounding Services LLC db a Fagron Sterile Services, 8710 E 34th St N, Wichita, KS 67226-2636 5038 Outsourcing Facility
FEI number
3012104093
FDA district office on the cover
Lenexa, KS 66214
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically,

A) Visual inspection of finished drug product is performed by inspectors without adequate training and qualification. Visual inspection training does not include showing inspectors examples of the types of defects they are looking for. Additionally, the firm does not have defect library of possible defects. Furthermore, inspectors have not been tested to establish their ability to locate defects and categorize them as required in their visual inspection form .

B) Visual inspection is not performed as required by the firm's written procedure. I observed the visual inspection Mitomycin lot 160829@001F (BUD 1115/16) by <Redacted B6,7,C> . Per the firm's written procedme Visual Inspection and Defect Recognition (9.200.FSS), the operators mustl <Redacted B4> however I observed this was not done on any of the syringes in the lot. ...

Read the full 483 (PDF on fda.gov)

Observation 2

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically,

A) The firm's <Redacted B4>, which <Redacted B4> such as <Redacted B4> has had approximately 766 critical alarms in areas used for production since March 8, 2016. The firm has not documented deviations and performed investigations on any of these alarms they have deemed critical. Alarm records are not reviewed concurrently with batch records at product release. The firm does not have a written procedure describing the alarms, their classifications, and when investigations are required.

B) Mitomycin lot 160406@_001F was released without conducting <Redacted B4> to ensure <Redacted B4> was lost and never tested, and the firm did not recognize this and investigate appropriately prior to release of the lot. An investigation conducted after lot release did not establish how/where the <Redacted B4> was lost.

Observation 3

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.

Specifically,

During the aseptic production of Mitomycin Bladder Irrigation Solution 20mg/40mL in 60 mL Syringes lot 160829@001F on 8/29/16, I observed:

a) Personnel performing the aseptic compounding and filling of sterile drug product wear masks which are not sterile and which the outer surface has not been shown to be non-linting/non-shedding. These masks have small fibers too numerous to count protruding from their outer surface.

b) The non-sterile masks and sterile cloth hoods worn by operators have an air gap between them, and the operator's skin can be seen between the mask and hood at some times during production .

Observation 4

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

Specifically,

Media fill records do not document a significant worst-case step occurring. During syringe filling of Mitomycin lot 160829@001F, I observed the oeerator fill syringes, then <Redacted B4>. This step is the only time the product is outside a closed system and exposed to air from the filling environment, but it is not documented as having occurred during the media fills and is also not documented in product batch records.

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Fagron Compounding Services dba Fagron Sterile Services). That is not a finding beyond this index’s search.

The Fagron Compounding Services dba Fagron Sterile Services pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming semaglutide under the labeler name “Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
71266-6100SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
71266-6110SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.